Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab Plus Polatuzumab-R-CHP for High-risk Diffuse Large B-cell Lymphoma
NCT05800366Phase 2Recruiting
- Start
- Apr 2023
- Primary completion
- Sep 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of glofitamab in diffuse large B-cell lymphoma (DLBCL). Started Apr 2023; status: recruiting.
02
Drugs
glofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05800366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05800366.